ArticleNoro psikiyatri arsivi2026
The Relationship Between Neurofilament Light Chain and B Lymphocyte Chemoattractant and Cognition in Multiple Sclerosis.
Article in Noro psikiyatri arsivi, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Multiple sclerosis (MS) is a chronic inflammatory, autoimmune, demyelinating disease of the central nervous system that is often associated with cognitive impairment. This study aims to investigate whether Neurofilament light chain (NfL) and B Lymphocyte Chemoattractant (CXCL13) are potential biomarkers for detecting cognitive impairment in MS. Methods: 57 patients with Radiologically Isolated Syndrome (RIS), Clinically Isolated Syndrome (CIS) or Relapsing-remitting MS (RRMS) and 70 healthy controls were studied. NfL and CXCL13 were measured by ELISA (the Enzyme-Linked ImmunoSorbent Assay) in the patients' cerebrospinal fluid (CSF) and serum samples. The Turkish-validated version of Brief International Cognitive Assessment for MS (BICAMS) test was applied. Serum biomarker levels and cognition tests were compared between the control and patient groups. Results: Serum NfL and CXCL13 values were significantly higher in the patient group (p = 0.043 and p < 0.001, respectively) compared to healthy controls. BICAMS were lower in the patient group (p<0.001). CSF CXCL13 levels demonstrated a significant negative correlation (p = 0.034) with California Verbal Learning Test-2 (CVLT-II) subtest scores, while CSF NfL levels showed a trend towards a negative association (p=0.067) with this subtest. There were no significant relationships between the serum or CSF biomarkers and the BICAMS total scores. Conclusion: NfL and CXCL13 potential biomarkers may not be associated with cognitive impairment in MS patients. The limitations of this study include the absence of CSF data from healthy individuals and the lack of stratification by clinical MS subtypes (RIS, CIS, or RRMS). Since they have been seen as promising biomarkers in MS, further studies are needed to determine this potential relationship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.